Amphastar Pharmaceuticals, Inc.

As of June 30, 2026, Amphastar Pharmaceuticals, Inc. carries a market capitalization of 858.30M, placing it among publicly traded companies globally. Its enterprise value stands at 1.26B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Amphastar Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for March 4, 2027.

As of June 30, 2026, Amphastar Pharmaceuticals, Inc. has 42.53M shares outstanding.

As of June 30, 2026, Amphastar Pharmaceuticals, Inc. trades at a trailing price-to-earnings ratio of 11.65. The price-to-sales ratio is 1.25, and the price-to-book ratio stands at 1.12.

As of June 30, 2026, Amphastar Pharmaceuticals, Inc. trades at an EV/EBITDA multiple of 7.02 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.72 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.99 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Amphastar Pharmaceuticals, Inc. trades at an EV/FCF ratio of 7.26, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.26B versus a market cap of 858.30M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Amphastar Pharmaceuticals, Inc. maintains a current ratio of 2.40, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 89.61, indicating elevated leverage, while an interest coverage ratio of 6.85 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Amphastar Pharmaceuticals, Inc. posted a return on equity (ROE) of 10.30, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.13 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.68, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.88, useful for judging operating efficiency across full business cycles. The company generates approximately 367,028.15 in revenue per employee across its workforce of 1,989.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.06 indicates how many times Amphastar Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Amphastar Pharmaceuticals, Inc. recorded 23.48M in income tax expense. That works out to an effective tax rate of 23.01, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 102.02M, leaving 78.55M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on November 6, 2026, Amphastar Pharmaceuticals, Inc.'s stock has gained approximately 17.58% over the past 52 weeks. The 50-day moving average sits at 25.35, while the 200-day moving average is 22.29.

Over the twelve months ended June 30, 2026, Amphastar Pharmaceuticals, Inc. generated 730.02M in revenue and converted that into 78.55M in net income, yielding earnings per share of 1.69. EBITDA reached 178.99M, while operating income came in at 114.29M.

As of June 30, 2026, Amphastar Pharmaceuticals, Inc. holds 290.12M in cash and equivalents against 688.32M in total debt, resulting in a net debt position of 388.44M. Total book value stands at 768.16M, with working capital of 367.75M providing operational flexibility.

Amphastar Pharmaceuticals, Inc. produced 184.61M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -31.72M in capital expenditures, free cash flow totaled 152.89M - equivalent to 3.37 per share.

Over the twelve months ended June 30, 2026, Amphastar Pharmaceuticals, Inc. posted a gross margin of 47.68, reflecting its pricing power and cost economics. The operating margin of 15.66 and net profit margin of 10.76 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 16.34, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 11.24, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Amphastar Pharmaceuticals, Inc. shareholders.

As of June 30, 2026, Amphastar Pharmaceuticals, Inc. has an Altman Z-Score of 2.84, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.